Reaktionsgleichung
[NH2:1][C:2]1[C:7]([N+:8]([O-:10])=[O:9])=[C:6]([N:11]2[CH2:16][CH2:15][N:14]([CH2:17][C:18](NC3SC=CN=3)=O)[CH2:13][CH2:12]2)[C:5](Br)=[CH:4][N:3]=1.[Cl:27]C1C(Cl)=CN=C(N)C=1[N+]([O-])=O.CCN(C(C)C)C(C)C.C(N1CCNCC1)C>CC(O)C>[Cl:27][C:5]1[C:6]([N:11]2[CH2:16][CH2:15][N:14]([CH2:17][CH3:18])[CH2:13][CH2:12]2)=[C:7]([N+:8]([O-:10])=[O:9])[C:2]([NH2:1])=[N:3][CH:4]=1Komponenten
6
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
This was prepared using the same procedure as for 2-(4-(2-amino-5-bromo-3-nitropyridin-4-yl)piperazin-1-yl)-N-(thiazol-2-yl)acetamide, but here using 4,5-dichloro-3-nitropyridin-2-amine (75 mg, 0.36 mmol), iPrOH (2 mL), DIPEA (3.5 eq, 1.26 mmol, 0.22 mL) and 1-ethylpiperazine (1.2 eq, 0.43 mmol, 0.05 mL). Concentration in vacuo and purification by preparative tlc (CH2Cl2-MeOH, 95:5) gave the product (32 mg, 31%) as a yellow solid;
Aufarbeitung
- customThis was prepared
- concentrationConcentration
- customin vacuo and purification by preparative tlc (CH2Cl2-MeOH, 95:5)
Quellen und Nachweise
- ORD-Eintrag
- ord-6d8ce21d3d684d39bd7600be43ef4a93
- Quelldatensatz
- uspto-grants-2012_01
- Patentnummer
- US08088761B2
Verknüpfte Notizen
Wird geladen…